Scarica l'app Stockscreener
0.5861
1.68%
0.0097
Precedente Chiudi:
$0.5764
Aprire:
$0.578
Volume 24 ore:
11,309
Relative Volume:
0.23
Capitalizzazione di mercato:
$2.64M
Reddito:
$7,500
Utile/perdita netta:
$-9.84M
Rapporto P/E:
-0.1024
EPS:
-5.7263
Flusso di cassa netto:
$-9.25M
1 W Prestazione:
+0.19%
1M Prestazione:
-1.00%
6M Prestazione:
-29.48%
1 anno Prestazione:
-59.86%
Intervallo 1D:
$0.578
$0.5957
Intervallo di 1 settimana:
$0.5682
$0.6092
Portata 52W:
$0.5038
$1.4934
Oragenics Inc Stock (OGEN) Company Profile
Nome
Oragenics Inc
Settore
Industria
Telefono
813-286-7900
Indirizzo
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.5861 | 2.64M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc Borsa (OGEN) Ultime notizie
Form 4 Oragenics Inc For: 7 July By Investing.com - Investing.com Nigeria
Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 - citybuzz -
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Oragenics Appoints New Chief Financial Officer and Leader - TipRanks
Price to earnings forward of Oragenics Inc. – AMEX:OGEN - TradingView
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Significant EPS Beat Amidst No Revenue ReportedGuidance vs Actual - dars.gov.et
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
OGENOragenics Inc Short Interest - Finviz
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc (OGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oragenics Inc (OGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Spread - newsline.com
OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Volatility Report - newsline.com
OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com
OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com
Oragenics Inc. (OGEN) Gains Ground: Potential Breakout Above $0.65 in Sight?Swing Trade Setups - newsline.com
OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com
Oragenics Inc. (OGEN) Edges Lower to $0.60, Testing Key Support LevelsEarnings Quality Factor - newsline.com
OGEN Q2 2023 Earnings: EPS Beats Estimates by Over 50% as Company Advances PipelineBanking Earnings Report - newsline.com
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
ORAGENICS INC (OGEN) Stock Chart - ChartMill
OGEN Q2 2023 Earnings: Narrower-than-expected loss as EPS beats estimates by over 50%Earnings Forecast Report - dars.gov.et
Oragenics Inc. (OGEN) Inches Higher as Stock Tests Key Resistance Near $0.64SuperTrend Flip - newsline.com
Oragenics Inc. (OGEN) Slips Amid Low Volume, Hovers Near Key SupportIceberg Order - newsline.com
Oragenics Inc. (OGEN) Edges Higher as Biotech Volatility PersistsIceberg Order - The Legal Advocate
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentOpen Signal Network - Newser
OGEN | Oragenics Inc. Executive Compensation - Quiver Quantitative
Oragenics Q2 2023 Earnings: Narrowing Loss Surprises, No Revenue YetFull Year Guidance - Newser
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - marketscreener.com
Oragenics (OGEN) Rallies +4.50% as Bulls Target $0.63 2026-05-20Community Buy Signals - Newser
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment - MEXC
Oragenics Highlights Investor Outreach at Micro-Cap Conference - TipRanks
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 - Yahoo Finance
Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device - TradingView
ORAGENICS PROVIDES INVESTOR UPDATE - Sahm
Oragenics (OGEN) Q2 2023 Earnings Surprise: EPS $-1.51, Up SignificantBanking Earnings Report - Newser
Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion - citybuzz -
Oragenics advances concussion drug trial, signs device LOI - Investing.com UK
Oragenics advances concussion drug trial, signs device LOI By Investing.com - Investing.com Nigeria
OGEN Technical Analysis | Trend, Signals & Chart Patterns | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics Inc Azioni (OGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):